Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead,

 Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and    Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and                              Foundation Medicine  Editor Note: For more information about this release, please scroll to bottom.  PR Newswire  NEW YORK, March 10, 2014  NEW YORK, March 10, 2014 /PRNewswire/ --  Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register  Arrowhead Research Corp. Analyst Notes  On March 3, 2014, Arrowhead Research Corp. (Arrowhead) announced that it has received a regulatory approval to initiate a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection. According to Arrowhead, the Hong Kong Department of Health issued a Certificate for Clinical Trial that allows the Company to proceed with its planned single-dose study of ARC-520 in two cohorts at two dose levels to be conducted at Queen Mary Hospital and Prince of Wales Hospital in Hong Kong. Arrowhead reported that the site initiation was completed and patient screening will begin shortly. The Company added that the topline study results are expected to be available in Q3 2014. The full analyst notes on Arrowhead Research Corp. are available to download free of charge at:  http://www.AnalystsReview.com/03102014/ARWR/report.pdf  ANI Pharmaceuticals, Inc. Analyst Notes  On March 5, 2014, ANI Pharmaceuticals, Inc. (ANI) announced the pricing of a firm commitment underwritten public offering of 1,402,525 shares of the Company's common stock at a purchase price to the public of $31.00 per share. ANI reported that net proceeds to the Company are estimated to be $43.5 million, before estimated offering expenses payable by the Company. ANI added that the offering is expected to close on or about March 10, 2014, and it has granted the underwriters a 30-day option to purchase up to an additional 210,378 shares. The Company stated that it anticipates utilizing the net proceeds of the offering to research, develop, commercialize, and expand its drug products, to acquire complementary businesses and technologies, and for working capital and general corporate purposes. The full analyst notes on ANI Pharmaceuticals, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03102014/ANIP/report.pdf  OraSure Technologies, Inc. Analyst Notes  On March 5, 2014, OraSure Technologies, Inc.'s (OraSure) stock advanced 11.37%, ending the day at $8.23. Over the previous three trading sessions, shares of OraSure climbed 18.58%, compared to the Nasdaq Composite which increased 1.16% during the same period. The full analyst notes on OraSure Technologies, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03102014/OSUR/report.pdf  Rigel Pharmaceuticals, Inc. Analyst Notes  On March 4, 2014, Rigel Pharmaceuticals, Inc. (Rigel) released its Q4 2013 and full-year 2013 results. Rigel registered quarterly revenues of $5.8 million in Q4 2013, with no comparable revenues in Q4 2012, while annual revenues were $7.2 million in full year 2013, compared to $2.3 million in full year 2012. The Company posted quarterly net loss of $16.9 million or $0.19 per diluted share, compared to net loss of $25.5 million or $0.30 per diluted share in Q4 2012; while annual net loss came in at $89.0 million or $1.02 per diluted share, compared to net loss of $98.8 million or $1.32 per diluted share in full year 2012. James M. Gower, Rigel Chairman and CEO, said, "As 2014 unfolds, Rigel has a number of significant clinical research projects in the works, which include a good combination of more advanced projects, such as fostamatinib in ITP, and earlier ones, such as R118 in intermittent claudication." Gower added, "We look forward to initiating the first of our two pivotal P3 trials of fostamatinib in ITP next month." The full analyst notes on Rigel Pharmaceuticals, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03102014/RIGL/report.pdf  Foundation Medicine, Inc. Analyst Notes  On March 5, 2014, Foundation Medicine, Inc.'s (Foundation Medicine) stock closed at $35.53, up 7.76%. Over the previous three trading sessions, Foundation Medicine's shares fell 0.28%, compared to the Nasdaq Composite which rose 1.16% during the same period. The full analyst notes on Foundation Medicine, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03102014/FMI/report.pdf  About Analysts Review  We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.  EDITOR NOTES:    oThis is not company news. We are an independent source and our views do     not reflect the companies mentioned.   oInformation in this release is fact checked and produced on a best efforts     basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are     only human and are prone to make mistakes. If you notice any errors or     omissions, please notify us below.   oThis information is submitted as a net-positive to companies mentioned, to     increase awareness for mentioned companies to our subscriber base and the     investing public.   oIf you wish to have your company covered in more detail by our team, or     wish to learn more about our services, please contact us at pubco [at]     AnalystsReview.com.   oFor any urgent concerns or inquiries, please contact us at compliance [at]     AnalystsReview.com.   oAre you a public company? Would you like to see similar coverage on your     company? Send us a full investors' package to research [at]     AnalystsReview.com for consideration.  COMPLIANCE PROCEDURE  Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.  NOT FINANCIAL ADVICE  Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.  NO WARRANTY OR LIABILITY ASSUMED  Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.  CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.  SOURCE Analysts Review  Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972  
Press spacebar to pause and continue. Press esc to stop.